UnitedHealth Group has grown into a healthcare behemoth with a market capitalization of approximately $297 billion. At the end of the last fiscal year, the company held over $75 billion in cash, cash equivalents, available-for-sale debt securities and equity securities. This war chest provides significant flexibility to invest in care delivery innovation, strategic acquisitions and debt reduction. The firm has increased its dividend for 16 consecutive years, achieving a 10-year dividend growth rate of 19.3%. With a current payout ratio near 46%, management retains ample room to support future increases while funding growth initiatives.

Beacon Investment Advisory Services reduced its position in UnitedHealth Group by 90.4% during the third quarter, selling 18,239 shares and ending the period with 1,938 shares valued at $669,000. Other institutions were net buyers: Capital Advisors Ltd. LLC boosted its stake by 4.8% to 1,550 shares worth $535,000; HBW Advisory Services added 934 shares (up 7.7%) to reach 13,049 shares valued at $4.506 million; Cohen Klingenstein inched up its holding by 0.3% to 17,250 shares worth $5.956 million; Burns Matteson Capital Management established a new stake valued at $2.768 million; and SWS Partners raised its position by 7.2% to 4,325 shares valued at $1.493 million. Hedge funds and other institutional investors collectively own 87.86% of the company’s shares.

In the most recent quarter, UnitedHealth reported earnings per share of $2.92, beating consensus estimates by $0.05, and generated revenue of $113.16 billion, roughly flat with expectations. Net margin stood at 4.04%, while return on equity was 19.23%. Revenue increased 12.2% year-over-year, reflecting strength across both UnitedHealthcare and Optum segments. The company declared a quarterly dividend of $2.21 per share, translating to an annualized payout of $8.84 and a yield of 2.7%. Seventeen analysts maintain buy ratings, nine rate the stock as hold and three as sell, with a consensus price objective of $385.54. Several firms recently revised their outlooks: Royal Bank of Canada and KeyCorp raised their targets to $408 and $400 respectively, Goldman Sachs initiated coverage with a buy rating, Deutsche Bank downgraded to hold at $333, and Mizuho increased its target to $430.